We are live on ! Find out more
VTGN icon

VistaGen Therapeutics
VTGN

92 hedge funds and large institutions have $9.13M invested in VistaGen Therapeutics in 2022 Q3 according to their latest regulatory filings, with 17 funds opening new positions, 33 increasing their positions, 26 reducing their positions, and 37 closing their positions.

New
Increased
Maintained
Reduced
Closed

2,121% more call options, than puts

Call options by funds: $422K | Put options by funds: $19K

27% more repeat investments, than reductions

Existing positions increased: 33 | Existing positions reduced: 26

1.33% less ownership

Funds ownership: 2.24% → 0.91% (-1.3%)

18% less funds holding

Funds holding: 112 → 92 (-20)

54% less first-time investments, than exits

New positions opened: 17 | Existing positions closed: 37

92% less capital invested

Capital invested by funds: $110M → $9.13M (-$101M)

100% less funds holding in top 10

Funds holding in top 10: 2 → 0 (-2)

Holders
92
Holders Change
-20
Holders Change %
-17.86%
% of All Funds
1.58%
Holding in Top 10
–
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-100%
% of All Funds
–
New
17
Increased
33
Reduced
26
Closed
37
Calls
$422K
Puts
$19K
Net Calls
+$403K
Net Calls Change
-$665K

Top Buyers

Rank Fund Capital Flow
1
GCP
GSA Capital Partners
United Kingdom
+$1.68M
2
Renaissance Technologies
Renaissance Technologies
New York
+$969K
3
State Street
State Street
Massachusetts
+$574K
4
Two Sigma Investments
Two Sigma Investments
New York
+$262K
5
Bank of America
Bank of America
North Carolina
+$144K

Top Sellers

Rank Fund Capital Flow
1
VA
VR Adviser
New York
-$18.2M
2
NMC
NEA Management Company
Maryland
-$14.3M
3
CC
Commodore Capital
New York
-$11.5M
4
ACP
Acuta Capital Partners
California
-$10M
5
NIP
Nicholas Investment Partners
California
-$3.92M
Name Holding Trade Value Shares
Change 		Change in
Stake
X
76
Xponance
Pennsylvania
$2K +$30 +3 +0.9%
Cambridge Investment Research Advisors
77
Cambridge Investment Research Advisors
Iowa
$2K +$3.48K +351 New
BWM
78
Boyd Wealth Management
California
$2K +$4.02K +406 New
TLCM
79
Twin Lakes Capital Management
California
$2K +$4.13K +417 New
Mariner
80
Mariner
Kansas
$2K +$4.24K +428 New
SS
81
Simplicity Solutions
Minnesota
$2K +$4.81K +485 New
MML Investors Services
82
MML Investors Services
Massachusetts
$2K +$4.96K +500 New
AWS
83
Atria Wealth Solutions
New York
$1.52K – – –
Barclays
84
Barclays
United Kingdom
$1K -$505 -51 -16%
GWSG
85
GPS Wealth Strategies Group
Colorado
$1K – – –
NAS
86
Nicolet Advisory Services
Wisconsin
$1K – – –
SWM
87
Selective Wealth Management
Virginia
$1K – – –
VA
88
VR Adviser
New York
– -$18.2M -689,910 Closed
NMC
89
NEA Management Company
Maryland
– -$14.3M -543,420 Closed
O
90
OrbiMed
New York
– -$11.8K -447,376 Closed
CC
91
Commodore Capital
New York
– -$11.5M -434,969 Closed
ACP
92
Acuta Capital Partners
California
– -$10M -378,715 Closed
NIP
93
Nicholas Investment Partners
California
– -$3.92M -148,528 Closed
SFM
94
Sphera Funds Management
Israel
– -$2.9M -109,705 Closed
EP
95
EPIQ Partners
Minnesota
– -$1.15M -43,378 Closed
SCM
96
Soleus Capital Management
Connecticut
– -$726K -27,500 Closed
OFA
97
Oak Family Advisors
Illinois
– -$344K -13,025 Closed
UOC
98
UBS O'Connor
Illinois
– -$336K -12,717 Closed
Assenagon Asset Management
99
Assenagon Asset Management
Luxembourg
– -$317K -12,016 Closed
HT
100
HAP Trading
New York
– -$292K -11,053 Closed
2 3
4
5 6

VTGN Hedge Fund Activity: Q3 2022 in Review

92 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in VistaGen Therapeutics (VTGN) for Q3 2022, worth a combined $9.13M — down 92% from $110M a quarter earlier.

Sellers outnumbered buyers: 37 funds closed out of VTGN and 17 opened new positions — a net loss of 20 holders — while 26 trimmed existing stakes and 33 added.

The largest buyer was GSA Capital Partners, adding an estimated $1.68M. The largest seller was VR Adviser, exiting entirely with an estimated $18.2M sold.

  • 92 institutional investors held VistaGen Therapeutics (VTGN) as of Q3 2022, down from 112 in Q2 2022.
  • Funds reported $9.13M of VistaGen Therapeutics stock for Q3 2022, down 92% quarter-over-quarter.
  • 17 funds opened new VistaGen Therapeutics positions in Q3 2022 and 37 closed out, a net change of -20 holders.
  • The largest VistaGen Therapeutics buyer in Q3 2022 was GSA Capital Partners, an estimated $1.68M added.
  • The largest VistaGen Therapeutics seller in Q3 2022 was VR Adviser, an estimated $18.2M sold.

Based on aggregated 13F filings for Q3 2022.